Bristol-Myers Squibb Gestione

Criteri Gestione verificati 3/4

Bristol-Myers Squibb Il CEO è Chris Boerner, nominato in Nov2023, e ha un mandato di 2.83 anni. la retribuzione annua totale è $ 18.79M, composta da 8.2% di stipendio e 91.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.006% delle azioni della società, per un valore di € 5.37M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 5.2 anni.

Informazioni chiave

Chris Boerner

Amministratore delegato

US$18.8m

Compenso totale

Percentuale dello stipendio del CEO	8.18%
Mandato del CEO	2yrs
Proprietà del CEO	0.006%
Durata media del management	2.1yrs
Durata media del Consiglio di amministrazione	5.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chris Boerner rispetto agli utili di Bristol-Myers Squibb?
Data	Compenso totale	Stipendio	Utili della società
Sep 30 2025	n/a	n/a	US$6b
Jun 30 2025	n/a	n/a	US$5b
Mar 31 2025	n/a	n/a	US$5b
Dec 31 2024	US$19m	US$2m	-US$9b
Sep 30 2024	n/a	n/a	-US$7b
Jun 30 2024	n/a	n/a	-US$7b
Mar 31 2024	n/a	n/a	-US$6b
Dec 31 2023	US$8m	US$1m	US$8b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$7b
Dec 31 2022	US$7m	US$1m	US$6b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$7m	US$1m	US$7b
Sep 30 2021	n/a	n/a	-US$5b
Jun 30 2021	n/a	n/a	-US$5b
Mar 31 2021	n/a	n/a	-US$6b
Dec 31 2020	US$6m	US$953k	-US$9b
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$563m
Mar 31 2020	n/a	n/a	US$954m
Dec 31 2019	US$6m	US$891k	US$3b

Compensazione vs Mercato: La retribuzione totale di Chris ($USD 18.79M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 5.29M ).

Compensazione vs guadagni: La retribuzione di Chris è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Chris Boerner (54 yo)

2yrs

Mandato

US$18,787,618

Compensazione

Dr. Christopher S. Boerner, also known as Chris, Ph.D. served as Chief Operating Officer at Bristol-Myers Squibb Company since April 26, 2023 to 2023 and served as its Executive Vice President since April...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Boerner	CEO & Chairman	2yrs	US$18.79m	0.0062% € 5.4m
David Elkins	Executive VP & CFO	6yrs	US$8.71m	0.0082% € 7.1m
Karin Shanahan	Executive VP	less than a year	US$6.57m	0.00089% € 768.2k
Greg Meyers	Executive VP and Chief Digital & Technology Officer	3.8yrs	Nessun dato	0.00097% € 837.3k
Charles Triano	SVP & Head of Investor Relations	no data	Nessun dato	Nessun dato
Kimberly Jablonski	Chief Compliance & Ethics Officer	2.1yrs	Nessun dato	Nessun dato
Cari Gallman	Executive Vice President	less than a year	Nessun dato	0.00054% € 466.1k
Ahn Poole	Executive VP & Chief People Officer	1.8yrs	Nessun dato	0.00026% € 224.4k
Joseph Eiden	Head of Medical Affairs	no data	Nessun dato	Nessun dato
Adam Lenkowsky	Executive VP & Chief Commercialization Officer	no data	Nessun dato	0.0012% € 1.0m
Wendy Bartie	Executive Vice President of Corporate Affairs	3.8yrs	Nessun dato	0.00028% € 241.7k
Robert Plenge	Executive VP & Chief Research Officer	2.3yrs	Nessun dato	0.00089% € 768.2k

2.1yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di BRM è considerato esperto (durata media dell'incarico 2.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Boerner	CEO & Chairman	2.8yrs	US$18.79m	0.0062% € 5.4m
Derica Rice	Independent Director	5.2yrs	US$390.00k	Nessun dato
Phyllis Yale	Independent Director	6yrs	US$380.00k	Nessun dato
Manuel Hidalgo Medina	Independent Director	4.4yrs	US$350.00k	Nessun dato
Peter Arduini	Independent Director	9.6yrs	US$376.79k	Nessun dato
Deepak Bhatt	Independent Director	3.4yrs	US$350.00k	Nessun dato
Theodore Samuels	Lead Independent Director	8.8yrs	US$440.00k	0.0017% € 1.5m
Paula Price	Independent Director	5.2yrs	US$380.00k	Nessun dato
Julia Haller	Independent Director	6yrs	US$390.00k	0.00067% € 578.3k
Michael McMullen	Independent director	1.3yrs	US$185.86k	Nessun dato
Karen Vousden	Independent Director	7.8yrs	US$350.00k	Nessun dato

5.2yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BRM sono considerati esperti (durata media dell'incarico 5.2 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/11/28 06:26
Prezzo dell'azione a fine giornata	2025/11/28 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Bristol-Myers Squibb Company è coperta da 44 analisti. 26 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
David Toung	Argus Research Company
Charles Butler	Barclays
Luisa Hector	Berenberg

Bristol-Myers Squibb Gestione

Criteri Gestione verificati 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Bristol Myers Squibb Announces Management Changes

Bristol Myers Squibb Announces Executive Changes

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Recent updates

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

State of Texas Sues Bristol-Myers Squibb and Sanofi for Deceptive Marketing of Blood Thinner Plavix

Bristol Myers Squibb in Collaboration with Johnson & Johnson Announces Update on Phase 3 Librexia ACS Trial

Bristol-Myers Squibb Company Updates Earnings Guidance for the Year 2025

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (Deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Systimmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-Bren, an EGFR X HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors At ESMO 2025

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Orbital Therapeutics, Inc. for $1.5 billion.

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-To-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib)

Bristol-Myers Squibb Company Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb Company to Report Q3, 2025 Results on Oct 30, 2025

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on November 3, 2025

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (Mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Systimmune Inc. and Bristol Myers Squibb Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Systimmune Inc

Bristol Myers Squibb's Application for Breyanzi (Lisocabtagene Maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Bristol Myers Squibb Announces Management Changes

Bristol Myers Squibb's Supplemental New Drug Application for Sotyktu (Deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Defensive Index

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels

Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on August 1, 2025

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo®? (nivolumab) Across Multiple Solid Tumor Indications

Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? (Nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1%

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT).

Bristol Myers Squibb Announces Executive Changes

Bristol-Myers Squibb Company Revises Earnings Guidance for the Year 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Squibb Announces U.S. Food and Drug Administration Updates CAMZYOS®? (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Opdivo (nivolumab) Plus Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

U.S. Food and Drug Administration Approves Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications

Us Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2025 Results on Apr 24, 2025

Bristol-Myers Squibb Company (NYSE:BMY) agreed to acquire 2seventy bio, Inc. (NasdaqGS:TSVT) for approximately $280 million.

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Bristol Myers Squibb Receives European Commission Approval for Opdivo®? (Nivolumab) Plus Yervoy®? (Ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Bristol-Myers Squibb Company Announces Quarterly Dividend on Common Stock, Payable on May 1, 2025

Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company Provides Update on Phase 3 Relativity-098 Trial

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (Lisocabtagene Maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Bristol Myers Squibb Receives Positive Chmp Opinion for Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Presents Results from Checkmate -8Hw Analysis Evaluating Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) Compared to Opdivo Monotherap

Bristol Myers Squibb Announces FDA Approval of Cobenfy

Third quarter dividend of US$0.62 announced

Upcoming dividend of US$0.62 per share

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb Company to Report Q4, 2024 Results on Feb 06, 2025

Bristol Myers Squibb Company Declares Quarterly Dividend, Payable on February 3, 2025

Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings released: EPS: US$0.60 (vs US$0.94 in 3Q 2023)

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

Upcoming dividend of US$0.60 per share

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Second quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma